Improving your health since 2000
n: val-PROE-ik AS-id Class: Anticonvulsant Divalproex Sodium
- Tablets, delayed-release 125 mg
- Tablets, delayed-release 250 mg
- Tablets, delayed-release 500 mg
- Capsules, sprinkle 125 mg
- Tablets, ER 250 mg
- Tablets, ER 500 mg
- Injection 100 mg/mL
- Capsules 250 mg (as valproic acid)
- Syrup 250 mg per 5 mL
- Capsules, delayed-release 125 mg (as valproic acid)
- Capsules, delayed-release 250 mg (as valproic acid)
- Capsules, delayed-release 500 mg (as valproic acid)
Believed to work by increasing brain levels of GABA.
Valproic acid is rapidly absorbed in the GI tract. Divalproex and valproic acid dissociates into valproate ion in the GI tract. T max is 4 to 17 h (ER tablets).
Vd of total or free valproic acid is 11 and 92 L per 1.73 m 2 , respectively. 80% to 90% protein bound (concentration-dependent).
Metabolized primarily in the liver.
30% to 50% excreted as glucuronide conjugate in the urine. The half-life is 9 to 16 h for valproate.
Protein binding in renal failure patients is substantially reduced.Hepatic Function Impairment
Cl may be decreased and unbound fraction of valproate may be increased.Elderly
Intrinsic Cl is reduced 39%; the free fraction is increased 44%.Children
Children between 3 and 10 yr of age have a 50% higher Cl than adults. Older than the age of 10 yr, pharmacokinetic parameters in children approximate those of adults.Gender
Adjusted unbound Cl similar between men and women.Race
Pharmacokinetics have not been studied.
Monotherapy and adjunctive therapy in treating patients with complex partial seizures that occur either in isolation or in association with other types of seizures; sole and adjunctive therapy in treating simple and complex absence seizures and adjunctively in patients with multiple seizure types that include absence seizures.Divalproex sodium delayed-release tablets
Treatment of manic episodes associated with bipolar disorder; prophylaxis of migraine headache.Divalproex sodium ER tablets
Treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features; prophylaxis of migraine headache.Valproic acid delayed-release capsules
Treatment of manic episodes associated with bipolar disorder; monotherapy and adjunctive therapy in patients with multiple seizure types that include absence seizures; prophylaxis of migraine headaches.
Bipolar disorder, borderline personality disorder, rectal administration.
Hepatic disease or dysfunction; known urea cycle disorders; hypersensitivity to the drug.
Therapeutic serum levels for most patients with seizures range from 50 to 100 mcg/mL; however, a good correlation has not been established between daily dose, serum level, and therapeutic effect.Complex Partial Seizures
PO / IV Start at 10 to 15 mg/kg daily and increase by 5 to 10 mg/kg/wk to achieve optimal clinical response, which usually occurs below 60 mg/kg daily.Conversion to monotherapy
PO / IV Start at 10 to 15 mg/kg daily and increase by 5 to 10 mg/kg/wk to achieve optimal clinical response, which usually occurs below 60 mg/kg daily. Concomitant antiepilepsy drug dosage can usually be reduced approximately 25% every 2 wk. The reduction may be started at initiation of therapy or delayed by 1 to 2 wk if there is a concern that reductions may result in seizures.Adjunctive therapy
PO / IV Divalproex sodium or valproic acid may be added to the patient's regimen at a dosage of 10 to 15 mg/kg daily. The dosage may be increased by 5 to 10 mg/kg/wk to achieve optimal response, which usually occurs below 60 mg/kg daily. If the total daily dose exceeds 250 mg, administer in divided doses.Conversion from Depakote to Depakote ER
Patients with epilepsy previously receiving Depakote should be administered Depakote ER daily using a dose that is 8% to 20% higher than the daily dose of Depakote . For patients whose Depakote total daily dose cannot be directly converted to Depakote ER , consider, at the clinician's discretion, an increase in the patient's Depakote total daily dose to the next higher dosage before converting to the appropriate total daily dose of Depakote ER .Mania
Increase dose as rapidly as possible to achieve the lowest therapeutic dose that produces the desired clinical effect (max, 60 mg/kg/day).Adults Divalproex sodium delayed-release tablets, valproic acid delayed-release capsules
PO 750 mg daily in divided doses.Divalproex sodium ER tablets
PO 25 mg/kg/day once daily.Migraine (Divalproex Sodium)
PO Start with 250 mg twice daily (max, 1,000 mg daily).Adults Divalproex sodium ER tablets
PO Start with 500 mg daily for 1 wk, thereafter increasing to 1,000 mg daily.Migraine (Valproic Acid)
PO Valproic acid delayed-release capsules: Start with 250 mg twice daily. Some patients may benefit from dosages of up to 1,000 mg daily.Simple and Complex Absence Seizures
PO / IV Start at 15 mg/kg daily, increasing at 1-wk intervals by 5 to 10 mg/kg daily until seizures are controlled or adverse reactions preclude further increases (max, 60 mg/kg daily). If the total daily dose exceeds 250 mg, administer in divided doses.
Store at 59° to 77°F.Sprinkle capsules
Store below 77°F.Oral solution, delayed-release tablets
Store below 86°F.Delayed-release capsules, ER tablets
Store at 59° to 86°F.Injection
Store at 59° to 86°F. Parenteral solutions may be stored for at least 24 h at 59° to 86°F when stored in glass or polyvinyl chloride bags.
Enhanced CNS depression.Amitriptyline/Nortriptyline, barbiturates, diazepam, ethosuximide, hydantoins (eg, phenytoin), phenobarbital, primidone, zidovudine
Plasma levels of these drugs may be increased.Carbamazepine
Carbamazepine plasma levels may be decreased while carbamazepine-10,11-epoxide levels may be increased; decreased valproic acid levels.Carbapenem antibiotics (eg, ertapenem, imipenem, meropenem), charcoal, cholestyramine, rifampin
May decrease valproic acid levels.Chlorpromazine, erythromycin, felbamate, fluoxetine, salicylates
May increase valproic acid levels.Clonazepam
Absence status may be induced in patients with a history of absence-type seizures.Hormonal contraceptives
Valproic acid plasma concentrations may be reduced, decreasing the efficacy.Lamotrigine
Decreased valproic acid levels; increased lamotrigine levels.Lorazepam
Lorazepam plasma levels may be increased.Olanzapine
Risk of hepatic adverse reactions may be increased; olanzapine levels may be decreased.Tolbutamide
May be displaced from binding site by valproate, transiently increasing tolbutamide levels. Clinical importance is not known.Topiramate
Coadministration with valproic acid has been associated with hyperammonemia with and without encephalopathy. Plasma levels of both drugs may be decreased.Warfarin
Warfarin may be displaced from its protein binding site, transiently increasing the anticoagulant effect.
Valproic acid may yield false-positive results on urine ketone tests; altered thyroid function tests.
Arrythmia, hypertension, hypotension, palpitation, postural hypotension, tachycardia, vasodilation (more than 1% and less than 5%); bradycardia (postmarketing).
Tremor (57%); headache (31%); somnolence (30%); asthenia (27%); dizziness (25%); insomnia (15%); nervousness (11%); ataxia (8%); amnesia (7%); abnormal thinking, emotional lability (6%); depression (5%); abnormal dreams, abnormal gait, agitation, anxiety, catatonic reaction, confusion, dysarthria, hallucinations, hypertonia, hypokinesia, incoordination, increased reflexes, paresthesia, personality disorder, speech disorder, tardive dyskinesia, vertigo (more than 1% and less than 5%); aggression, behavioral deterioration, cerebral atrophy, dementia, emotional upset, encephalopathy, hostility, hyperactivity, hypesthesia, parkinsonism, psychosis (postmarketing).
Alopecia (24%); rash (6%); discoid lupus erythematosus, dry skin, furunculosis, maculopapular rash, petechiae, pruritus, seborrhea (more than 1% and less than 5%); bruising, cutaneous vasculitis, erythema multiforme, photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis (postmarketing).
Diplopia (16%); amblyopia, blurred vision (12%); nystagmus, pharyngitis (8%); tinnitus (7%); abnormal vision, conjunctivitis, deafness, dry eyes, ear pain/disorder, epistaxis, eye pain, otitis media, photophobia, taste perversion (more than 1% and less than 5%); hearing loss, spots before eyes (postmarketing).
Nausea (48%); vomiting (27%); abdominal pain, diarrhea (23%); dyspepsia (13%); anorexia (12%); increased appetite (6%); constipation (5%); dry mouth, eructation, fecal incontinence, flatulence, gastroenteritis, GI disorder, glossitis, hematemesis, increased appetite, pancreatitis, periodontal abscess, stomatitis, tooth disorder (more than 1% and less than 5%); abdominal cramps, acute pancreatitis (postmarketing).
Amenorrhea, cystitis, dysmenorrhea, dysuria, metrorrhagia, urinary frequency, urinary incontinence, vaginal hemorrhage, vaginitis (more than 1% and less than 5%); breast enlargement, enuresis, galactorrhea, irregular menses, UTI (postmarketing).
Thrombocytopenia (24% [high dose]); ecchymosis (5%); anemia, increased bleeding time, leukopenia (more than 1%); acute intermittent porphyria, agranulocytosis, aplastic anemia, bone marrow suppression, eosinophilia, frank hemorrhage, hematoma, hypofibrinogenemia, inhibition of platelet aggregation, macrocytosis, pancytopenia, relative lymphocytosis (postmarketing).
Increased ALT and AST (more than 1% and less than 5%); bilirubin, increased LDH (postmarketing).
Injection-site pain (3%); injection-site reaction (2%).
Weight gain (9%); peripheral edema (8%); weight loss (6%); edema, hypoproteinemia (more than 1% and less than 5%); Fanconi syndrome (primarily in children), hyperammonemia, hyperglycemia, hypernatremia, SIADH (postmarketing).
Back pain (8%); neck pain, neck rigidity (1% or more); arthralgia, leg cramps, myalgia, myasthenia, twitching (more than 1% and less than 5%); bone pain, weakness (postmarketing).
Flu-like syndrome (12%); bronchitis, dyspnea, rhinitis (5%); hiccup, increased cough, pneumonia, sinusitis (more than 1% and less than 5%).
Infection (20%); pain (11%); accidental injury, fever (6%); chest pain, chills, face edema, fungal infection, malaise, viral infection (more than 1% and less than 5%); abnormal thyroid function tests, anaphylaxis, coma, fever, hypothermia, lupus erythematosus, parotid gland swelling (postmarketing).
Increased risk in children younger than 2 yr of age, especially those on multiple anticonvulsants or those with congenital metabolic disorders, severe seizure disorders, mental retardation, or organic brain syndrome. Onset is typically during the first 6 mo.Pancreatitis, some cases life-threatening
Occurs in children and adults after initial or long-term therapy.Teratogenicity
Can produce teratogenic effects such as neural tube defects (eg, spina bifida).
Periodic plasma concentrations of valproate are recommended during the early course of therapy when drugs capable of enzyme induction are coadministered.
Category D .
Excreted in breast milk.
Use with extreme caution in children younger than 2 yr of age (see Warning Box). Safety and efficacy of divalproex sodium for treatment of acute mania not established in patients younger than 18 yr of age. Safety and efficacy of divalproex sodium for the prophylaxis of migraines not established in patients younger than 16 yr of age. Safety and efficacy of divalproex sodium ER tablets for the prophylaxis of migraine headaches in children have not been established. Safety and efficacy of divalproex ER tablets and valproic acid delayed-release capsules for the treatment of complex partial seizures, simple and complex absence seizures, and multiple seizure types that include absence seizures not established in children younger than 10 yr of age. Safety and efficacy of valproate sodium injection not established in children younger than 2 yr of age.
Reduce starting dose and base therapeutic dose on clinical response.
Because IV valproic acid has been associated with a higher incidence of death than IV phenytoin, do not use in the prevention of posttraumatic seizures in patients with acute head injuries.
Abrupt discontinuation may precipitate status epilepticus with attendant life-threatening hypoxia in patients receiving valproic acid to prevent major seizures.
Thrombocytopenia, inhibition of secondary phase of platelet aggregation, and abnormal coagulation parameters (eg, low fibrinogen) may occur. Risk of bleeding may be increased.
Reactions usually occur within first 6 mo of therapy and are preceded by symptoms such as anorexia, facial edema, jaundice, lethargy, lost seizure control, malaise, vomiting, and weakness. Use drug with caution in patients with history of liver disease. Monitor patients and perform LFTs frequently.
May occur despite normal LFTs. In patients who develop unexplained lethargy and vomiting or changes in mental status, consider hyperammonemic encephalopathy and measure ammonia level. If ammonia is elevated, discontinue valproic acid.
A decrease in body core temperature to less than 95°F has been reported in association with valproate therapy.
Clinical data from long-term studies (more than 3 wk) are not available.
Has been reported in close association with the initiation of valproate therapy.
Life-threatening pancreatitis has been reported.
Suicidal ideation may be a manifestation of certain psychiatric disorders and may persist until significant remission of symptoms occurs.
Asterixis, death, deep coma, heart block, motor restlessness, somnolence, visual hallucinations.
Copyright © 2009 Wolters Kluwer Health.